Clinical Trial Update: Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating albumin-bound paclitaxel followed by epirubicin with cyclophosphamide in triple-negative breast cancer is ongoing, with status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer | Phase 4 | Status: UNKNOWN